Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients

Clinical Transplantation

Volumn 21, Issue 4, 2007, Pages 441-448

  Oppenheimer, Federico ^a   Gonzalez Molina, Miguel ^b   Rubio, Marta ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c Health Outcomes Research Europe   (Spain)

Author keywords

Cost; Cytomegalovirus; Ganciclovir; Prophylaxis; Valganciclovir

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; VALGANCICLOVIR;

ARTICLE; CATHETER OCCLUSION; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG COST; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; INJECTION SITE EXTRAVASATION; INJECTION SITE PHLEBITIS; MAJOR CLINICAL STUDY; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPAIN;

ADMINISTRATION, ORAL; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG COSTS; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFUSIONS, INTRAVENOUS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 34547478860     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2007.00612.x     Document Type: Article

References (34)

1. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002: 2: 850.
2. Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004: 17: 357.
3. Sagedal S, Hartmann A, Nordal KP et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004: 66: 329.
4. Valantine HA, Gao SZ, Menon SG et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999: 100: 61.
5. Giral M, Nguyen JM, Daguin P et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001: 12: 1758.
6. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004: 4: 928.
7. Mc Carthy JM, Karim MA, Krueger H, Keown PA. The cost impact of cytomegalovirus disease in renal transplant recipients. Transplantation 1993: 55: 1277.
8. Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busuttil RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995: 60: 1357.
9. Seu P, Winston DJ, Holt CD, Kaldas F, Busuttil RW. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997: 64: 1614.
10. Noble S, Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998: 5: 115.
11. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000: 70: 1174.
12. Paya C, Humar A, Dominguez E et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004: 4: 611.
13. Pescovitz MD. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transpl Infect Dis 1999: 1 (Suppl. 1): 31.
14. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000: 44: 2811.
15. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000: 30 (Suppl. 2): S171.
16. Trotta MP, Ammassari A, Melzi S et al., AdICoNA Study Group. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002: 31 (Suppl. 3): S128.
17. Pescovitz MD. Formulary considerations for drugs used to prevent cytomegalovirus disease. Am J Health Syst Pharm 2003: 60 (23 Suppl. 8): S17.
18. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999: 67: 315.
19. Das A. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients. Hepatology 2000: 31: 311.
20. Somerville KT. Cost advantages of oral drug therapy for managing cytomegalovirus disease. Am J Health Syst Pharm 2003: 60 (23 Suppl. 8): S9.
21. F. Hoffmann-La Roche Ltd. Valcyte (Valganciclovir Hydrochloride Tablets). Complete Product Information: F. Hoffmann-La Roche Ltd, 2003.
22. Sanjurjo M, Requena T, Requena ME, Fernández I. Estimación de costes asociados a los fármacos en el ámbito hospitalario. Propuesta de un modelo. Farmacoeconomía 1995: 1: 9.
23. Slof J, Badia X, Lizán L et al. Zoledronic acid versus pamidronate: Cost minimization in bone metastasis. J Med Econ 2005: 8: 1.
24. Soikos. Base de datos de costes sanitarios [Health Care Costs Database]. Barcelona: Centro de estudios de Economia de la Salud y Politica Social, 2003.
25. Cano T, Galvez R. Aproximación al coste del transplante hepático en el Hospital Ramón y Cajal. Revista española de trasplantes 1998: 7: 6.
26. P érez Romero C, M artin Martin JJ, L ópez del Amo González MP et al. Costes basados en actividades de los programas de transplantes de riñón, hígado y corazón en siete hospitales espanoles: Fundación Signo, 2002, [cited Oct 31st 2004]. Available at: http://www.fundacionsigno.com. Premio Professor Barea Primera Edición 2002.
27. Garcia Latorre FJ, Dolsac Espinosa JI, Cebrian Martin C, Lorente Valero F, Bastaros Garcia JC. Economic-health care indicators in 2 health areas: The cost of the "consultation product" of primary health teams. Aten Primaria 1994: 14: 655.
28. Ma FC. Análisis del coste de la visita domiciliaria de enfermería a inmovilizados: Aproximación al estudio de la eficiencia. Atención Primaria 1997: 19; 110.
29. Humar A et al. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005: 192: 1154.
30. Ruiz-Laiglesia FJ, Torrubia-Perez CB, Reclusa-Poyo F, Arnal-Rubio N. Phlebitis in peripheral venous catheters. Med Clin (Barc) 1994: 103: 116.
31. Falagas ME, Arbo M, Ruthazer R et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997: 63: 1595.
32. Das A. Cytomegalovirus infection in solid organ transplantation: economic implications. Pharmacoeconomics 2003: 21: 467.
33. Claxton AJ, Cramer J, Pierce C. Asystematic review of the associations between dose regimens and medication compliance. Clin Ther 2001: 23: 1296.
34. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002: 35: 866.